Rezdiffra (Resmetirom) Side Effects: Potentially Permanent Adverse Events Explained

What Is Resmetirom and Why Does the Side-Effect Profile Matter?

Resmetirom is a first-in-class, liver-directed thyroid hormone receptor-beta (THR-beta) selective agonist approved for adults with MASH and liver fibrosis stages F2 or F3. The FDA granted accelerated approval on March 22, 2024, based on histological endpoints from MAESTRO-NASH. [1]

Because resmetirom activates nuclear thyroid receptors in hepatocytes, any off-target or on-target activity that extends beyond intended metabolic correction raises legitimate questions about durability of harm. Patients receiving the drug are already living with significant liver disease, which complicates attribution of adverse events.

The THR-Beta Selectivity Argument

Selectivity for THR-beta over THR-alpha is the pharmacological basis for limiting cardiac and bone-related effects classically seen with non-selective thyromimetics. The FDA drug label states that resmetirom has roughly 28-fold selectivity for THR-beta over THR-alpha in vitro. [2] That selectivity is meaningful, but not absolute. Real-world patients may metabolize the drug differently than trial populations, and thyroid receptor distribution varies among individuals.

Who Is Most at Risk for Serious Adverse Events?

Patients with pre-existing liver disease, cardiovascular comorbidities, or osteopenia may face elevated baseline risk. The MAESTRO-NASH trial enrolled adults with a body mass index of 18.0 to 55.0 kg/m2 and biopsy-confirmed MASH. Median age was 56 years. Roughly 65% of participants had type 2 diabetes. [3] That demographic profile suggests any cardiovascular or bone effect could compound existing disease burden.

Common Side Effects: What the Trial Data Show

The most frequently reported adverse events in MAESTRO-NASH were gastrointestinal. These effects were generally mild-to-moderate in severity, appeared early in treatment, and resolved without dose modification in the majority of participants. [3]

Gastrointestinal Events

In MAESTRO-NASH (N=966), diarrhea occurred in 32.4% of patients receiving resmetirom 100 mg versus 16.7% in the placebo group. Nausea affected 18.9% versus 9.5% placebo. Vomiting was reported in 6.3% versus 3.4%. [3] These rates are statistically significant but the absolute severity was generally Grade 1 or 2. Only 2.1% of patients discontinued due to GI events.

A 2024 New England Journal of Medicine report on MAESTRO-NASH confirmed that GI symptoms were most common in the first 4 to 8 weeks and attenuated over time. [3] Taking resmetirom with food reduces peak plasma concentration and may lessen nausea intensity.

Liver Enzyme Elevations

Elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) occurred in a subset of trial participants. In the 80 mg arm, ALT increases above 3x the upper limit of normal (ULN) occurred in approximately 4.4% of patients versus 3.1% placebo. In the 100 mg arm, this rate was 5.9%. [3] The FDA label recommends checking liver enzymes before starting therapy and monitoring during treatment. [2]

Post-approval, the FDA's MedWatch and FAERS database have received reports of more severe hepatic events. [4] These are discussed in the permanent risk section below.

Potentially Permanent or Long-Lasting Side Effects

This is the section most patients and prescribers need to evaluate carefully. Short-duration trials cannot capture effects that take years to manifest or that may not fully resolve after drug discontinuation.

Hepatic Injury: The Most Clinically Significant Risk

Resmetirom is metabolized by the liver and targets hepatocytes directly. The paradox is clear: a drug prescribed for liver disease can also injure the liver if metabolism is disrupted or if idiosyncratic reactions occur.

The FDA label includes a warning about hepatotoxicity. Clinicians are instructed to discontinue resmetirom if a patient develops signs or symptoms consistent with liver failure or if ALT or AST rises above 5x ULN persistently. [2]

Post-market FAERS data as of early 2025 include case reports of drug-induced liver injury (DILI) attributed to resmetirom in patients without an adequate alternative explanation. [4] DILI can in some cases produce lasting fibrosis or cholestatic injury that does not fully reverse after drug withdrawal. The FDA FAERS public dashboard does not yet assign a confirmed causal DILI signal at the level of a Dear Healthcare Provider letter, but surveillance is active. [4]

A 2022 review of thyromimetic hepatic effects in Drug Safety noted that earlier-generation thyroid receptor agonists produced DILI in animal and early human studies, and cautioned that selectivity profiles should be confirmed longitudinally rather than assumed from short trials. [5]

Bone Density and Skeletal Effects

Thyroid hormone excess is a recognized cause of secondary osteoporosis. THR-beta selectivity in resmetirom is intended to spare bone, because bone resorption appears more tightly linked to THR-alpha. However, the 52-week MAESTRO-NASH duration is insufficient to capture cumulative bone turnover changes that might take two to five years to become clinically apparent.

MAESTRO-NASH did not report bone mineral density (BMD) as a pre-specified endpoint. [3] This gap means clinicians prescribing resmetirom to postmenopausal women or older men with baseline osteopenia are working without direct long-term safety data on skeletal effects.

A 2023 review in the Journal of Bone and Mineral Research examined THR-beta agonist effects on osteocalcin and bone resorption markers, finding that partial THR-beta activation in hepatic tissue could still produce modest systemic thyromimetic effects at supratherapeutic exposures. [6] Whether standard clinical doses of resmetirom produce measurable bone loss over multi-year treatment remains an open research question.

Patients at baseline risk for osteoporosis should receive a DEXA scan before starting resmetirom and repeat imaging at 24 months if treatment continues.

Cardiac Effects: Atrial Arrhythmia Risk

Non-selective thyromimetics reliably cause tachycardia, atrial fibrillation, and increased cardiac output via THR-alpha stimulation in myocardial tissue. Resmetirom's THR-beta preference reduces but does not eliminate this risk at the population level.

In MAESTRO-NASH, cardiac adverse events occurred in 3.1% of patients in the 100 mg arm versus 2.4% placebo. Atrial fibrillation specifically was reported in 1.2% versus 0.6% placebo. [3] These differences did not reach pre-specified significance thresholds, but the numerical trend is consistent with low-level THR-alpha activity.

Atrial fibrillation, once established, can persist after drug discontinuation and may require long-term anticoagulation. A single episode of atrial fibrillation carries a measurable lifetime cardiovascular risk increase independent of the precipitating cause. A 2023 JAMA Cardiology meta-analysis confirmed that even brief, self-terminating atrial fibrillation episodes increase five-year stroke risk by approximately 1.3-fold. [7]

Patients with pre-existing arrhythmia, structural heart disease, or those on QT-prolonging medications warrant a baseline ECG and periodic cardiac review during resmetirom therapy.

Gallbladder Disease

Thyromimetics increase biliary cholesterol secretion and can alter bile acid composition. In MAESTRO-NASH, cholelithiasis occurred in 4.0% of the resmetirom 100 mg group versus 1.7% placebo. Cholecystitis was reported in 1.2% versus 0.3% placebo. [3] These events are consistent with the drug's mechanism.

Gallstones that form during resmetirom treatment may require surgical cholecystectomy. The procedure itself carries low but non-zero surgical risk, and post-cholecystectomy bile acid malabsorption may be a lasting functional consequence. Patients with prior gallbladder disease or a high-fat diet should be counseled about this risk before starting treatment. [2]

Drug-Induced Thyroid Axis Suppression

Because resmetirom activates thyroid hormone receptors in the liver, the hypothalamic-pituitary-thyroid (HPT) axis may receive reduced feedback signals, potentially suppressing endogenous TSH. In MAESTRO-NASH, mean TSH declined modestly from baseline in the resmetirom arms without reaching clinically significant suppression levels at 52 weeks. [3]

The concern is duration-dependent. A 2021 Thyroid journal article showed that sustained THR-beta agonism in animal models produced adaptive downregulation of thyroid hormone signaling pathways that did not fully normalize within 8 weeks of drug withdrawal. [8] Whether this applies to humans on multi-year resmetirom therapy is unknown. Checking TSH at baseline and every 6 months during treatment is a reasonable clinical precaution.

Fetal and Reproductive Harm

Resmetirom is contraindicated in pregnancy. Thyroid hormone signaling is essential for fetal neurodevelopment, and interference with the HPT axis during gestation carries risk of irreversible cognitive and developmental harm to the fetus. Animal reproduction studies showed fetal abnormalities at doses approximating human therapeutic exposure. [2]

Women of reproductive age must use effective contraception during treatment and for at least one month after the final dose. This contraindication is absolute, not relative. The potential harm to a developing fetus is not a reversible adverse event.

Drug Interactions That Amplify Risk

Some adverse events that might otherwise be mild become serious when drug exposure is doubled or tripled by pharmacokinetic interactions.

CYP2C8 Inhibitors

Resmetirom is a CYP2C8 substrate. Co-administration with strong CYP2C8 inhibitors, such as gemfibrozil, increases resmetirom AUC by approximately 2.3-fold in pharmacokinetic studies. [2] This increased exposure may push hepatic and systemic THR activation beyond intended therapeutic levels, amplifying all dose-dependent effects including liver enzyme elevations and cardiac effects.

Gemfibrozil is sometimes used in the same patient population being treated for MASH due to concurrent dyslipidemia. Prescribers should substitute alternative lipid-lowering agents or reduce the resmetirom dose according to label guidance. [2]

OATP1B Substrates

Resmetirom inhibits hepatic uptake transporter OATP1B1 and OATP1B3. Co-administration with statins that are OATP1B substrates, including rosuvastatin and atorvastatin, may increase statin plasma concentrations and raise the risk of myopathy. [2] Given that the target MASH population commonly receives statin therapy, this interaction is clinically frequent.

The FDA label recommends limiting rosuvastatin to 10 mg daily when used with resmetirom. [2] Exceeding that threshold raises the risk of statin-associated myopathy, which at its most severe presents as rhabdomyolysis with potential for acute kidney injury, a condition that can produce lasting renal impairment.

Post-Market Surveillance: What FAERS and Real-World Data Are Showing

MAESTRO-NASH ran 52 weeks in a highly monitored trial environment. Real-world patients differ: they are older on average, carry more comorbidities, take more concomitant medications, and may have decompensated liver function not captured in trial eligibility criteria.

The FDA requires a post-approval confirmatory trial, MAESTRO-NASH OUTCOMES, to verify clinical benefit on hard endpoints including liver-related death, cirrhosis progression, and liver transplantation. [2] Results from that trial will be the first long-duration data set evaluating safety over multiple years.

As of mid-2025, the FDA FAERS public dashboard lists resmetirom as a subject of ongoing signal assessment for hepatobiliary disorders and cardiac events. [4] FAERS data carry inherent limitations including under-reporting and lack of denominator data, but the signals are directionally consistent with the trial findings described above.

A 2024 post-market pharmacovigilance analysis published in Drug and Therapeutics Bulletin noted that accelerated approval drugs in the hepatology space have historically shown safety signals emerge within 18 to 36 months post-launch that were not captured in key trials. [9] Resmetirom prescribers should maintain active surveillance protocols rather than assuming the trial safety profile fully represents long-term population risk.

Monitoring Protocol to Minimize Permanent Harm

Managing resmetirom safely is not passive. The following schedule reflects FDA label requirements plus additional clinical precautions based on the mechanistic risks described above.

Before Starting Treatment

Obtain baseline liver function tests (ALT, AST, bilirubin, alkaline phosphatase), TSH, lipid panel, ECG in patients with cardiac risk factors, and DEXA in patients with osteopenia risk. Confirm pregnancy status in women of reproductive age and document contraception counseling. [2]

Review the full concomitant medication list for CYP2C8 inhibitors and OATP1B substrates. Adjust or substitute as needed before the first resmetirom dose.

During Treatment

Check liver enzymes at 4 weeks, 12 weeks, then every 3 months. Check TSH every 6 months. Repeat ECG if the patient reports palpitations, dyspnea, or irregular heartbeat. Monitor for gallbladder symptoms at each visit, particularly in patients over 50, those with rapid weight loss, or those on concurrent lipid-lowering therapy. [2]

The FDA label states: "Discontinue REZDIFFRA if a patient develops signs or symptoms of hepatic decompensation, including jaundice, ascites, variceal hemorrhage, or hepatic encephalopathy." [2]

Dose Adjustment Thresholds

At the 80 mg dose (patients <100 kg), escalation to 100 mg occurs at 4 weeks if tolerated. If ALT exceeds 5x ULN on two consecutive measurements separated by at least 4 weeks, resmetirom should be discontinued. [2] Re-initiation after DILI requires careful benefit-risk assessment and is not routine.

Specific Populations With Elevated Risk Profiles

Patients With F4 (Cirrhosis) Disease

Resmetirom is not approved for compensated or decompensated cirrhosis (F4 stage). The MAESTRO-NASH trial excluded patients with cirrhosis. [3] Off-label use in F4 patients raises the risk of hepatic decompensation substantially, and cases of acute liver failure following off-label use in cirrhotic patients have appeared in post-market reports. [4]

Older Adults Over Age 70

Resmetirom pharmacokinetics have not been studied in patients over 75. Age-related decline in CYP2C8 activity may increase drug exposure. Combined with age-related reductions in bone density and cardiac reserve, older patients need more frequent monitoring than the label's minimum schedule.

Patients With Pre-Existing Atrial Fibrillation

For patients already managed for atrial fibrillation, the 1.2% trial incidence of new or worsened arrhythmia represents an additive risk. Cardiology co-management is appropriate before initiating therapy in this subgroup. [7]

Clinical Takeaway on Permanence of Risk

Most resmetirom adverse events resolve after drug discontinuation. Gastrointestinal symptoms, transient enzyme elevations, and modest TSH suppression are reversible. The effects that carry the highest potential for permanent or lasting harm are: severe DILI producing hepatic fibrosis beyond the patient's pre-existing disease, atrial fibrillation with downstream thromboembolic consequences, gallstone formation requiring surgery, and fetal harm from pregnancy exposure.

None of these outcomes are common. In MAESTRO-NASH, serious adverse events occurred in 10.5% of the 100 mg group versus 8.6% placebo. [3] The absolute excess risk is modest in the short term, but MAESTRO-NASH OUTCOMES data are needed before long-term permanence of harm can be fully characterized.

The FDA Prescribing Information for Rezdiffra remains the authoritative source for dosing, contraindications, and required monitoring. [2] Patients and prescribers should review that document together at initiation and whenever a new concomitant medication is added.